Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...

Results among Omada members taking GLP-1s for weight loss who entered into a discontinuation care track (n=63) showed that, on average, members were able to successfully maintain their weight 16 weeks ...

Entering the marketplace could help drive enrollment in Teladoc’s chronic care management programs, executives with the ...

At the J.P. Morgan Health Care conference, the future outlook for GLP-1 drugs used to treat obesity was a key focus, ...

Omada will run the experimental arm of the trial and provide engagement and outcome data for analysis. The trial will track weight loss and reduction in A1c blood sugar levels, and also the impact ...

The use of GLP-1 drugs sparked the term "Ozempic shaming" to describe the negative perceptions faced by those who choose ...

With the holidays past and the new year arrived, we look ahead — to losing weight. For some that resolve theoretically ...

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

Three people who lost weight sustainably after years of yo-yo dieting shared the most valuable lessons they learned about fat ...

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

Weight loss drugs like Wegovy, Ozempic, and Mounjaro show transformative effects in obesity, improving heart health and reducing dementia risks. However, studies reveal significant muscle and bone ...